Skip to main content

PPP3CA KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130), expandable thumbnail
  • Western blot - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130), expandable thumbnail
  • Cell Culture - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130), expandable thumbnail
  • Sanger Sequencing - Human PPP3CA (Calcineurin A) knockout HeLa cell line (AB265130), expandable thumbnail

Publications

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Alternative names

Alpha isoform formerly PPP2B, CALN, CALNA, CALNA 1, CAM-PRP catalytic subunit, CNA, CNA 1, CNA alpha, Calcineurin A alpha, Calcineurin A1, CalcineurinA, Calmodulin-dependent calcineurin A subunit alpha isoform, PP2BA_HUMAN, PPP2B, Ppp3ca, Protein phosphatase 2B catalytic subunit, Protein phosphatase 3 (formerly 2B) catalytic subunit alpha isoform, Protein phosphatase 3 catalytic subunit alpha isoform PPP3CA, Protein phosphatase 3 catalytic subunit alpha isozyme, Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform

Recommended products

PPP3CA KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
PPP3CA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Calcineurin A also known as PPP3CA is a highly specific protein phosphatase with a pivotal role in cellular signaling. It has a molecular mass of approximately 59 to 61 kDa depending on the isoform. Calcineurin A expression occurs in various tissues including the brain immune cells and cardiac tissues. It acts as the catalytic subunit of the enzyme calcineurin and is important for its function.

Biological function summary

Calcineurin A participates in numerous cellular processes through its phosphatase activity. As part of the calcineurin complex which includes a regulatory subunit it modulates the dephosphorylation of target proteins. This activity enables Calcineurin A to influence activation of T-lymphocytes by dephosphorylating the nuclear factor of activated T-cells (NFAT) a transcription factor responsible for immune response. Calcineurin A also plays a role in neuronal signaling and muscle function.

Pathways

Calcineurin A engages in the calcium signaling pathway which is vital for diverse cellular functions. It is related to proteins like calmodulin which binds calcium ions to activate Calcineurin A. Another important pathway includes the MAPK signaling pathway where Calcineurin A influences various cellular outcomes by regulating different transcription factors. Through these pathways Calcineurin A integrates signals that affect cellular growth survival and differentiation.

Associated diseases and disorders

Calcineurin A is associated with cardiac hypertrophy and immunosuppressive conditions. In cardiac hypertrophy aberrant Calcineurin A activity leads to changes in heart muscle size and function. The protein also connects to the disorder of immunosuppression through its inhibition by drugs like cyclosporine which are used to prevent transplant rejection by targeting Calcineurin A. This inhibition blocks T-cell activation and provides therapeutic benefits in managing transplant patients.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com